EMMA · Emmaus Life Sciences, Inc.

Revenue declined 17.6% year-over-year to $2.0 million from $2.4 million, primarily due to decreased U.S. sales as noted in management discussion. This erosion reflects competitive pressures in the Endari® market, where generic entrants have impacted demand, though the company continues to realize all revenues from Territory sales pending the NeoImmuneTech (NIT) agreement's Effective Date.

Operating income improved 16.0% to a loss of $823 thousand from $980 thousand, driven by a decrease in loss from operations. Management highlights cost discipline, including reductions tied to office lease modifications, headcount decreases, lower product testing, and settlement fees. These efforts narrowed the operating margin loss to -41.5%, demonstrating operational leverage amid revenue contraction.

Net income deteriorated to a $3.3 million loss from $2.3 million, worsening 43.1% year-over-year, with diluted EPS at -$0.05 versus -$0.04. The expansion stems from increased other expenses—mainly repayments of promissory and convertible notes—partially offset by the smaller operating loss. This dynamic highlights financing costs as a key drag on bottom-line results.

Cash flow from operations flipped to a $344 thousand use from $279 thousand provided last year, signaling heightened working capital needs or timing differences. Liquidity remains challenged, as the ability to meet liabilities, fund operations, service debt, fulfill Telcon API commitments, and execute the business plan is strained. The pending termination of the U.S. sales service agreement with NIT is expected to reduce selling expenses post-Effective Date, when Emmaus transitions to supplier with double-digit margins and royalties. However, no assurance exists for sales growth, profitability, or sufficient capital without operational cash flow or a strategic transaction.